Skip to main content
CDC Website

Researchers

Regional Approaches for Eradicating Tuberculosis (RAFET)

The United States Agency for International Development (USAID) is seeking applications for a Cooperative Agreement from qualified entities to implement the Regional Approaches for Eradicating Tuberculosis (RAFET) program in Central Asia. Eligibility for this award is restricted to qualified U.S. and Non-U.S. organizations.

 

Limited Competition: Specific Pathogen Free Macaque Colonies (U42 Clinical Trial Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to provide continuing support for specific pathogen-free (SPF) macaque colonies previously funded under the auspices of PAR-21-089 and PAR-18-669 that support Human Immunodeficiency Virus (HIV)/Acquired Immunodeficiency Syndrome (AIDS) research. Breeding colonies are essential to sustain appropriate SPF macaques for research related to HIV/AIDS. Pedigree SPF macaques are free of certain viruses, which may confound the results of HIV/AIDS-related investigations or present a risk to the personnel who care for the animals.

Strengthening Capacity of Central Asia and Eastern Europe Countries to Implement Sustainable and Effective HIV/AIDS Prevention, Care, and Treatment and Health Security Programs under PEPFAR

This NOFO aims to enhance Central Asia's capacity to provide high-quality HIV/AIDS prevention, treatment, laboratory, and strategic information (SI) programs. The goal is to achieve epidemic control by 2030, following international standards (e.g., UNAIDS, International Health Regulations), and adapted to the local context. Based on PEPFAR's 5x3 Strategic Framework (September 2022), the focus is on leveraging investments to build resilient health systems that can effectively respond to public health threats.

Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)

HIV infection and substance use are comorbid conditions that bidirectionally and synergistically influence the deleterious outcomes in people who suffer from substance use disorders (SUD). The persistence and transcriptional reactivation of HIV lead to the development of neuropathological complications. Strategies to address viral latency include silencing of HIV transcription and reactivation and clearance.

Chemical Probes and Drugs for Modulating HIV Transcription in the Context of Substance Use Disorders (R21 Clinical Trial Not Allowed)

HIV infection and substance use are comorbid conditions that bidirectionally and synergistically influence the deleterious outcomes in people who suffer from substance use disorders (SUD). The persistence and transcriptional reactivation of HIV lead to the development of neuropathological complications. Strategies to address viral latency include silencing of HIV transcription and reactivation and clearance.

Limited Competition: Revision Applications of Existing NIH Centers for AIDS Research (CFAR) and Developmental Centers for AIDS Research (D-CFAR) Grants (P30 Clinical Trial Not Allowed)

This notice of funding opportunity (NOFO) encourages revision applications from currently funded NIH Centers for AIDS Research (CFAR) and Developmental CFARs (D-CFAR) to expand the role of the CFARs and D-CFARs to include additional support and infrastructure for outreach and research related to HIV and HIV-related health disparities in the United States and globally. The goal of the NOFO is aimed towards diversifying and supporting the next generation of HIV/AIDS investigators, and engaging and mentoring these investigators in high-priority HIV/AIDS research.